Rich Allan | Brunswick Group
Rich Allan

Rich Allan

Director, New York

With extensive experience in scientific and financial communications, investor relations and public affairs, Rich provides strategic counsel to clients focused particularly on navigating the complex landscape of biopharma, biotech and healthcare policy.

He has led communications strategy in connection with major milestones and events, including clinical data announcements, company unveilings, M&A, issues management, partnerships and public engagement initiatives.

Prior to Brunswick, he was an executive at a boutique life sciences communications and investor relations firm, where he helped clients engage with investors, patient advocates and the scientific community. In an earlier role at Russo Partners, he led communications and investor relations strategy and execution for emerging and established biotechnology companies. His background in the industry includes work as a research scientist in biochemistry, oncology and developmental genetics.

Rich holds an M.Phil. in Biochemistry and Biophysics from Columbia University, a M.S. in Biology from New York University, and an A.B. in Molecular Biology from Princeton University.